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========================================================================================

The original version of this article unfortunately contained some mistakes. The corrected details are provided below:

**Page 806, column 1, line 3:** The text, which previously read:

'as and'

should read:

'as'

**Page 809, Table 2, column 6, row 29:** the cell, which was previously blank, should read:

'NR'

**Page 811, column 1, paragraph 2, sentence 4:** The two sets of bracketed text, which previously read:

'(once-weekly dulaglutide, liraglutide and exenatide ER)' and '(twice-daily exenatide and lixisenatide)'

should read:

'(once-daily liraglutide, once-weekly dulaglutide and once-weekly exenatide ER)' and '(twice-daily exenatide and once-daily lixisenatide)'

**Page 812, Table 3, column 3 and Page 814, Table 4, column 5:** The column headings, which previously read:

'Exenatide 20 mg/wk'

Should read:

'Exenatide 2 mg/wk'

**Page 814, Table 4, column 4:** The heading, which previously read:

'Dulaglutide 0.5/1.0 mg/wk'

Should read:

'Dulaglutide 1.5 mg/wk'

**Page 814, Table 4, column 5, row 7:** The 95% CI, which previously read:

'(83--1.00)'

Should read:

'(0.83--1.00)'

**Page 815, Table 5, footnote 'b', which previously read:**

Exenatide IR and liraglutide are short-acting; lixisenatide, dulaglutide, exenatide ER and semaglutide are long-acting

Should read:

Exenatide IR and lixisenatide are short-acting; dulaglutide, exenatide ER, liraglutide and semaglutide are long-acting.
